Clinical Trial Update: Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pegylated liposomal doxorubicin hydrochloride and carboplatin followed by surgery and paclitaxel in triple-negative breast cancer (Stag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Pegylated liposomal doxorubicin hydrochloride (pegylated liposomal doxorubicin)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-03-29